Article info
Review
Rituximab in neurological disease: principles, evidence and practice
- Correspondence to Dr Anu Jacob, The Walton Centre NHS Foundation Trust, Lower Ln, Liverpool L9 7LJ, UK; anu.jacob{at}thewaltoncentre.nhs.uk
Citation
Rituximab in neurological disease: principles, evidence and practice
Publication history
- First published November 29, 2018.
Online issue publication
January 17, 2019
Article Versions
- Previous version (29 November 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines
- Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders
- Neurodegeneration in multiple sclerosis and neuromyelitis optica
- Autologous haematopoietic stem cell transplantation for neurological diseases
- Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
- Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?
- A practical guide to the treatment of neuromyelitis optica
- Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis
- Humoral and cellular responses to SARS-CoV-2 vaccination in patients with autoantibody-mediated neuroimmunology
- Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort